Shortening of 3′UTRs correlates with poor prognosis in breast and lung cancer

PLoS ONE

Volumn 7, Issue 2, 2012, Pages

  Lembo, Antonio ^a   Di Cunto, Ferdinando ^a   Provero, Paolo ^a  

^a UNIVERSITY OF TURIN   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

MESSENGER RNA; MICRORNA; TRANS ACTING FACTOR;

3' UNTRANSLATED REGION; ARTICLE; BINDING SITE; BREAST CANCER; CANCER SURVIVAL; CELL PROLIFERATION; CELL TRANSFORMATION; CONTROLLED STUDY; GENE EXPRESSION; GENETIC REGULATION; GENETIC TRANSCRIPTION; HIGH THROUGHPUT SEQUENCING; HUMAN; LUNG CANCER; POLYMERASE CHAIN REACTION; POSTTRANSCRIPTIONAL GENE SILENCING; PROGNOSIS; TUMOR GROWTH; BREAST TUMOR; FEMALE; GENE EXPRESSION REGULATION; GENETICS; LUNG TUMOR; MALE; RNA INTERFERENCE;

3' UNTRANSLATED REGIONS; BREAST NEOPLASMS; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; LUNG NEOPLASMS; MALE; MICRORNAS; PROGNOSIS; RNA INTERFERENCE;

EID: 84856710408     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0031129     Document Type: Article

References (69)

1. Bushati N, Cohen SM, (2007) microRNA functions. Annu Rev Cell Dev Biol 23: 175-205.
2. Croce CM, (2009) Causes and consequences of microRNA dysregulation in cancer. Nat Rev Genet 10: 704-714.
3. Shi XB, Tepper CG, deVere White RW, (2008) Cancerous miRNAs and their regulation. Cell Cycle 7: 1529-1538.
4. Shi M, Liu D, Duan H, Shen B, Guo N, (2010) Metastasis-related miRNAs, active players in breast cancer invasion, and metastasis. Cancer Metastasis Rev 29: 785-799.
5. Kumar MS, Pester RE, Chen CY, Lane K, Chin C, et al. (2009) Dicer1 functions as a haploinsuf-ficient tumor suppressor. Genes Dev 23: 2700-2704.
6. Martello G, Rosato A, Ferrari F, Manfrin A, Cordenonsi M, et al. (2010) A microRNA targeting Dicer for metastasis control. Cell 141: 1195-1207.
7. Melo SA, Ropero S, Moutinho C, Aaltonen LA, Yamamoto H, et al. (2009) A TARBP2 mutation in human cancer impairs microRNA processing and DICER1 function. Nat Genet 41: 365-370.
8. Millevoi S, Vagner S, (2010) Molecular mechanisms of eukaryotic pre-mRNA 3′ end processing regulation. Nucleic Acids Res 38: 2757-2774.
9. Sandberg R, Neilson JR, Sarma A, Sharp PA, Burge CB, (2008) Proliferating cells express mRNAs with shortened 3′ untranslated regions and fewer microRNA target sites. Science 320: 1643-1647.
10. Mayr C, Bartel DP, (2009) Widespread shortening of 3′UTRs by alternative cleavage and polyadeny-lation activates oncogenes in cancer cells. Cell 138: 673-684.
11. Fu Y, Sun Y, Li Y, Li J, Rao X, et al. (2011) Differential genome-wide profiling of tandem 3′ UTRs among human breast cancer and normal cells by high-throughput sequencing. Genome Res 21: 741-747.
12. Ji Z, Tian B, (2009) Reprogramming of 3′ untranslated regions of mRNAs by alternative polyadeny-lation in generation of pluripotent stem cells from different cell types. PLoS One 4: e8419.
13. Thomsen S, Azzam G, Kaschula R, Williams LS, Alonso CR, (2010) Developmental RNA processing of 3′UTRs in Hox mRNAs as a context-dependent mechanism modulating visibility to microRNAs. Development 137: 2951-2960.
14. Ji Z, Lee JY, Pan Z, Jiang B, Tian B, (2009) Progressive lengthening of 3′ untranslated regions of mRNAs by alternative polyadenylation during mouse embryonic development. Proc Natl Acad Sci U S A 106: 7028-7033.
15. Singh P, Alley TL, Wright SM, Kamdar S, Schott W, et al. (2009) Global changes in processing of mRNA 3′ untranslated regions characterize clinically distinct cancer subtypes. Cancer Res 69: 9422-9430.
16. Gautier L, Mller M, Friis-Hansen L, Knudsen S, (2004) Alternative mapping of probes to genes for Affymetrix chips. BMC Bioinformatics 5: 111.
17. Zhang H, Hu J, Recce M, Tian B, (2005) PolyA DB: a database for mammalian mRNA polyadeny-lation. Nucleic Acids Res 33: D116-D120.
18. Lee JY, Yeh I, Park JY, Tian B, (2007) PolyA DB 2: mRNA polyadenylation sites in vertebrate genes. Nucleic Acids Res 35: D165-D168.
19. Pawitan Y, Bjhle J, Amler L, Borg AL, Egyhazi S, et al. (2005) Gene expression profiling spares early breast cancer patients from adjuvant therapy: derived and validated in two population-based cohorts. Breast Cancer Res 7: R953-R964.
20. Miller LD, Smeds J, George J, Vega VB, Vergara L, et al. (2005) An expression signature for p53 status in human breast cancer predicts mutation status, transcriptional effects, and patient survival. Proc Natl Acad Sci U S A 102: 13550-13555.
21. Uhlmann S, Zhang JD, Schwger A, Mannsperger H, Riazalhosseini Y, et al. (2010) miR-200bc/429 cluster targets PLCgamma1 and differentially regulates proliferation and EGF-driven invasion than miR-200a/141 in breast cancer. Oncogene 29: 4297-4306.
22. Gregory PA, Bert AG, Paterson EL, Barry SC, Tsykin A, et al. (2008) The miR-200 family and miR-205 regulate epithelial to mesenchymal transition by targeting ZEB1 and SIP1. Nat Cell Biol 10: 593-601.
23. Webster RJ, Giles KM, Price KJ, Zhang PM, Mattick JS, et al. (2009) Regulation of epidermal growth factor receptor signaling in human cancer cells by microRNA-7. J Biol Chem 284: 5731-5741.
24. Reddy SDN, Ohshiro K, Rayala SK, Kumar R, (2008) MicroRNA-7, a homeobox D10 target, inhibits p21-activated kinase 1 and regulates its functions. Cancer Res 68: 8195-8200.
25. Kastl L, Brown I, Schofield AC, (2011) miRNA-34a is associated with docetaxel resistance in human breast cancer cells. Breast Cancer Res Treat doi:10.1007/s10549-011-1424-3.
26. Pogribny IP, Filkowski JN, Tryndyak VP, Golubov A, Shpyleva SI, et al. (2010) Alterations of microRNAs and their targets are associated with acquired resistance of MCF-7 breast cancer cells to cisplatin. Int J Cancer 127: 1785-1794.
27. Foekens JA, Sieuwerts AM, Smid M, Look MP, de Weerd V, et al. (2008) Four miRNAs associated with aggressiveness of lymph node-negative, estrogen receptor-positive human breast cancer. Proc Natl Acad Sci U S A 105: 13021-13026.
28. Shevde LA, Metge BJ, Mitra A, Xi Y, Ju J, et al. (2010) Spheroid-forming subpopulation of breast cancer cells demonstrates vasculogenic mimicry via hsa-miR-299-5p regulated de novo expression of osteopontin. J Cell Mol Med 14: 1693-1706.
29. Guttilla IK, White BA, (2009) Coordinate regulation of FOXO1 by miR-27a, miR-96, and miR-182 in breast cancer cells. J Biol Chem 284: 23204-23216.
30. Lin H, Dai T, Xiong H, Zhao X, Chen X, et al. (2010) Unregulated miR-96 induces cell proliferation in human breast cancer by downregulating transcriptional factor FOXO3a. PLoS One 5: e15797.
31. Richardson AL, Wang ZC, Nicolo AD, Lu X, Brown M, et al. (2006) X chromosomal abnormalities in basal-like human breast cancer. Cancer Cell 9: 121-132.
32. Shedden K, Taylor JMG, Enkemann SA, Tsao MS, Yeatman TJ, et al. (2008) Gene expression- based survival prediction in lung adenocarcinoma: a multi-site, blinded validation study. Nat Med 14: 822-827.
33. hui Wang L, Xiang J, Yan M, Zhang Y, Zhao Y, et al. (2010) The mitotic kinase Aurora-A induces mammary cell migration and breast cancer metastasis by activating the Cofilin-F-actin pathway. Cancer Res 70: 9118-9128.
34. Ogawa E, Takenaka K, Katakura H, Adachi M, Otake Y, et al. (2008) Perimembrane Aurora-A expression is a significant prognostic factor in correlation with proliferative activity in non-small-cell lung cancer (NSCLC). Ann Surg Oncol 15: 547-554.
35. Savage K, Leung S, Todd SK, Brown LA, Jones RL, et al. (2008) Distribution and signi_cance of caveolin 2 expression in normal breast and invasive breast cancer: an immunouorescence and immunohistochemical analysis. Breast Cancer Res Treat 110: 245-256.
36. Wang JS, Wang FB, Zhang QG, Shen ZZ, Shao ZM, (2008) Enhanced expression of Rab27A gene by breast cancer cells promoting invasiveness and the metastasis potential by secretion of insulin-like growth factor-II. Mol Cancer Res 6: 372-382.
37. Scodan RL, Cizeron-Clairac G, Fourme E, Meseure D, Vacher S, et al. (2010) DNA repair gene expression and risk of locoregional relapse in breast cancer patients. Int J Radiat Oncol Biol Phys 78: 328-336.
38. Barbano R, Copetti M, Perrone G, Pazienza V, Muscarella LA, et al. (2010) High RAD51 mRNA expression characterize estrogen receptor-positive/progesteron receptor-negative breast cancer and is associated with patient's outcome. Int J Cancer.
39. Ko JC, Wang LH, Jhan JY, Ciou SC, Hong JH, et al. (2009) The role of celecoxib in Rad51 expression and cell survival affected by gefitinib in human non-small cell lung cancer cells. Lung Cancer 65: 290-298.
40. Tozlu-Kara S, Roux V, Andrieu C, Vendrell J, Vacher S, et al. (2007) Oligonucleotide microarray analysis of estrogen receptor alpha-positive postmenopausal breast carcinomas: identification of HRPAP20 and TIMELESS as outstanding candidate markers to predict the response to tamoxifen. J Mol Endocrinol 39: 305-318.
41. Xu X, Qiao M, Zhang Y, Jiang Y, Wei P, et al. (2010) Quantitative proteomics study of breast cancer cell lines isolated from a single patient: discovery of TIMM17A as a marker for breast cancer. Proteomics 10: 1374-1390.
42. Nagai MA, Gerhard R, Fregnani JHTG, Nonogaki S, Rierger RB, et al. (2011) Prognostic value of NDRG1 and SPARC protein expression in breast cancer patients. Breast Cancer Res Treat 126: 1-14.
43. Suzuki M, Hao C, Takahashi T, Shigematsu H, Shivapurkar N, et al. (2005) Aberrant methylation of SPARC in human lung cancers. Br J Cancer 92: 942-948.
44. Schneider G, Nieznanski K, Jozwiak J, Slomnicki LP, Redowicz MJ, et al. (2010) Tubulin binding protein, CacyBP/SIP, induces actin polymerization and may link actin and tubulin cytoskeletons. Biochim Biophys Acta 1803: 1308-1317.
45. Wang N, Ma Q, Wang Y, Ma G, Zhai H, (2010) CacyBP/SIP expression is involved in the clinical progression of breast cancer. World J Surg 34: 2545-2552.
46. Nie F, Yu XL, Wang XG, Tang YF, Wang LL, et al. (2010) Down-regulation of CacyBP is associated with poor prognosis and the effects on COX-2 expression in breast cancer. Int J Oncol 37: 1261-1269.
47. Grande-Garca A, del Pozo MA, (2008) Caveolin-1 in cell polarization and directional migration. Eur J Cell Biol 87: 641-647.
48. Elsheikh SE, Green AR, Rakha EA, Samaka RM, Ammar AA, et al. (2008) Caveolin 1 and Caveolin 2 are associated with breast cancer basal-like and triple-negative immunophenotype. Br J Cancer 99: 327-334.
49. Bradshaw AD, Graves DC, Motamed K, Sage EH, (2003) SPARC-null mice exhibit increased adi- posity without significant differences in overall body weight. Proc Natl Acad Sci U S A 100: 6045-6050.
50. Sankaran S, Crone DE, Palazzo RE, Parvin JD, (2007) Aurora-A kinase regulates breast cancer associated gene 1 inhibition of centrosome-dependent microtubule nucleation. Cancer Res 67: 11186-11194.
51. Dutertre S, Descamps S, Prigent C, (2002) On the role of aurora-A in centrosome function. Oncogene 21: 6175-6183.
52. Kais Z, Barsky SH, Mathsyaraja H, Zha A, Ransburgh DJR, et al. (2011) KIAA0101 interacts with BRCA1 and regulates centrosome number. Mol Cancer Res.
53. Dodson H, Bourke E, Jeffers LJ, Vagnarelli P, Sonoda E, et al. (2004) Centrosome ampli_cation induced by DNA damage occurs during a prolonged G2 phase and involves ATM. EMBO J 23: 3864-3873.
54. Cappelli E, Townsend S, Griffin C, Thacker J, (2011) Homologous recombination proteins are associated with centrosomes and are required for mitotic stability. Exp Cell Res 317: 1203-1213.
55. Sderlund K, Skoog L, Fornander T, Askmalm MS, (2007) The BRCA1/BRCA2/Rad51 complex is a prognostic and predictive factor in early breast cancer. Radiother Oncol 84: 242-251.
56. Foltz DR, Jansen LET, Black BE, Bailey AO, Yates JR, et al. (2006) The human CENP-A centromeric nucleosome-associated complex. Nat Cell Biol 8: 458-469.
57. Yang X, Wood PA, Hrushesky WJM, (2010) Mammalian TIMELESS is required for ATM-dependent CHK2 activation and G2/M checkpoint control. J Biol Chem 285: 3030-3034.
58. Jorissen RN, Gibbs P, Christie M, Prakash S, Lipton L, et al. (2009) Metastasis-Associated Gene Expression Changes Predict Poor Outcomes in Patients with Dukes Stage B and C Colorectal Cancer. Clin Cancer Res 15: 7642-7651.
59. Sotiriou C, Wirapati P, Loi S, Harris A, Fox S, et al. (2006) Gene expression profiling in breast cancer: understanding the molecular basis of histologic grade to improve prognosis. J Natl Cancer Inst 98: 262-272.
60. Wang Y, Klijn JGM, Zhang Y, Sieuwerts AM, Look MP, et al. (2005) Gene-expression profiles to predict distant metastasis of lymph-node-negative primary breast cancer. Lancet 365: 671-679.
61. Desmedt C, Piette F, Loi S, Wang Y, Lallemand F, et al. (2007) Strong time dependence of the 76-gene prognostic signature for node-negative breast cancer patients in the TRANSBIG multicenter independent validation series. Clin Cancer Res 13: 3207-3214.
62. Wiestner A, Tehrani M, Chiorazzi M, Wright G, Gibellini F, et al. (2007) Point mutations and genomic deletions in CCND1 create stable truncated cyclin D1 mRNAs that are associated with increased proliferation rate and shorter survival. Blood 109: 4599-4606.
63. Zhang H, Lee JY, Tian B, (2005) Biased alternative polyadenylation in human tissues. Genome Biol 6: R100.
64. Irizarry RA, Bolstad BM, Collin F, Cope LM, Hobbs B, et al. (2003) Summaries of Affymetrix GeneChip probe level data. Nucleic Acids Res 31: e15.
65. Kao KJ, Chang KM, Hsu HC, Huang AT, (2011) Correlation of microarray-based breast cancer molecular subtypes and clinical outcomes: implications for treatment optimization. BMC Cancer 11: 143.
66. Bild AH, Yao G, Chang JT, Wang Q, Potti A, et al. (2006) Oncogenic pathway signatures in human cancers as a guide to targeted therapies. Nature 439: 353-357.
67. Zhu CQ, Ding K, Strumpf D, Weir BA, Meyerson M, et al. (2010) Prognostic and predictive gene signature for adjuvant chemotherapy in resected non-small-cell lung cancer. J Clin Oncol 28: 4417-4424.
68. Laurent C, Valet F, Planque N, Silveri L, Maacha S, et al. (2011) High PTP4A3 phosphatase expression correlates with metastatic risk in uveal melanoma patients. Cancer Res 71: 666-674.
69. Friedman RC, Farh KKH, Burge CB, Bartel DP, (2009) Most mammalian mRNAs are conserved targets of microRNAs. Genome Res 19: 92-105.